SIGA TECHNOLOGIES INC
SIGA evidence brief
What we can confirm
- BioSniper Score:
- 5.9 / 10
- Market Cap:
- $217.0M
- Lead Asset:
- tpoxx (Phase 3)
What it means
What to watch
Prepared research question
What matters most for SIGA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SIGA
SIGA Technologies Inc. is a commercial-stage pharmaceutical company focused on the development and commercialization of TPOXX (tecovirimat), an antiviral for smallpox and mpox, with a primary revenue stream from U.S. government stockpiling contracts and growing international sales.
Key risk: Government contract dependency
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 11 clinical trials · 1 catalyst · 2 FDA decisions for SIGA TECHNOLOGIES INC.
SIGA Technologies Inc. is a commercial-stage pharmaceutical company focused on the development and commercialization of TPOXX (tecovirimat), an antiviral for smallpox and mpox, with a primary revenue stream from U.S. government stockpiling contracts and growing international sales.
- Cash & equivalents of $117.6M as of 2026-06-30 [sec]
- Total revenue of $41.0M and net income of $12.5M for the quarter ended 2026-06-30 [sec]
- Shareholders' equity of $165.3M as of 2026-06-30 [sec]
- TPOXX is the company's sole marketed product, approved for smallpox and under study for mpox [pipeline]
- SIGA targets a Supplemental NDA submission for smallpox post-exposure prophylaxis in the first half of 2027 [sec_mda · as of 2026-08-06]
What works
- Strong cash position of $117.6M as of 2026-06-30 provides financial stability for operations and R&D [sec]
- Consistent profitability with net income of $12.5M in the latest quarter [sec]
- Diversifying revenue through international contracts, including a $13M order from an Asia Pacific country [news · published 2026-03-14]
- U.S. government funding of $27M for pediatric formulation and IV technology transfer supports pipeline expansion [news · published 2026-03-14]
What to weigh
- Heavy reliance on U.S. government contracts, with risks of non-completion or failure to secure new contracts [sec_mda · as of 2026-08-06]
- Nascent international biodefense market may not develop sufficiently to sustain international sales growth [sec_mda · as of 2026-08-06]
- Clinical trial results for TPOXX in mpox have been mixed, with three randomized placebo-controlled trials reporting topline results as of June 2026 [sec_mda · as of 2026-08-06]
- Revenue is lumpy and dependent on delivery milestones, creating potential volatility in financial results [news · published 2026-03-14]
From the filings
Quoted directly from source documents.
SIGA targets Supplemental NDA submission for smallpox PEP in first half of 2027
“the Company is currently targeting a Supplemental NDA submission in the first half of 2027”
SEC MD&A · August 6, 2026
SIGA received $27M in U.S. government funding for pediatric formulation and IV technology transfer
“SIGA has also obtained $27 million in U.S. government funding for pediatric formulation work and IV technology transfer for TPOXX”
News · March 14, 2026
Three randomized placebo-controlled mpox trials reported topline results as of June 30, 2026
“As of June 30, 2026, three of the randomized, placebo-controlled clinical trials reported topline results”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2032-08-08 · Patent_Expiry · TECOVIRIMAT — Patent_Expiry: NDA208627 — Patent expiry for TECOVIRIMAT (TPOXX) could open the door for generic competition after this date.
Risks & what to watch (4)›
Key risks
- Government contract dependency — Revenue heavily tied to U.S. government contracts; risk of non-completion or failure to secure new contracts [sec_mda · as of 2026-08-06]
- International market uncertainty — Nascent international biodefense market may not develop sufficiently to sustain sales growth [sec_mda · as of 2026-08-06]
- Mpox clinical trial outcomes — Mixed topline results from three mpox trials could affect label expansion or commercial prospects [sec_mda · as of 2026-08-06]
- Revenue lumpiness — Revenue recognition tied to delivery milestones, causing potential quarterly volatility [news · published 2026-03-14]
What to watch
- Supplemental NDA submission for smallpox PEP, targeted for first half of 2027 [sec_mda · as of 2026-08-06]
- Delivery of $13M oral TPOXX to international customer in Q2 2026 [news · published 2026-05-07]
- Delivery of $26M IV TPOXX to U.S. Strategic National Stockpile by end of Q3 2026 [news · published 2026-05-07]
- Progress on pediatric formulation and IV technology transfer funded by $27M U.S. government award [news · published 2026-03-14]
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 2, 2026 · How we verify sources →
Run SIGA TECHNOLOGIES INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SIGA TECHNOLOGIES INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.06 · 0% dilution
Lead: Phase 3
1 candidate
1 upcoming, next in ~2125d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
182
Total value held
$177.6M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 3,494,193 | $18.7M |
| dimensional fund advisors lp | 2,702,724 | $14.5M |
| altravue capital, llc | 2,432,024 | $13.0M |
| vanguard capital management llc | 1,714,380 | $9.2M |
| arrowstreet capital, limited partnership | 1,525,960 | $8.2M |
| american century companies inc | 1,317,784 | $7.1M |
| geode capital management, llc | 1,315,545 | $7.0M |
| aqr capital management llc | 1,219,677 | $6.5M |
| state street corp | 1,011,938 | $5.4M |
| first wilshire securities management inc | 890,498 | $4.8M |
Showing top 10 of 182 institutional holders of SIGA TECHNOLOGIES INC. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 7.5%
- Days to cover
- 4.6
- Shares short
- 3,481,817
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SIGA short interestGovernance
Frequently asked questions
What is the AI investment thesis for SIGA TECHNOLOGIES INC?
SIGA Technologies Inc. is a commercial-stage pharmaceutical company focused on the development and commercialization of TPOXX (tecovirimat), an antiviral for smallpox and mpox, with a primary revenue stream from U.S. government stockpiling contracts and growing international sales.
What is SIGA TECHNOLOGIES INC's lead drug candidate?
SIGA TECHNOLOGIES INC's most advanced tracked candidate is tpoxx (Phase 3) for Smallpox.
What is SIGA TECHNOLOGIES INC's next catalyst?
SIGA TECHNOLOGIES INC's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA208627" — expected August 8, 2032.
Who is the CEO of SIGA TECHNOLOGIES INC?
Dr. Diem Nguyen M.B.A., Ph.D. is the chief executive officer of SIGA TECHNOLOGIES INC (SIGA).
Where is SIGA TECHNOLOGIES INC headquartered?
SIGA TECHNOLOGIES INC (SIGA) is headquartered in New York, NY, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.